Loading organizations...
§ Private Profile · Boston, MA, USA
Biotechnology developing therapeutics for neuromuscular disorders, Duchenne muscular dystrophy, via intracellular drug delivery.
Entrada Therapeutics is a US biotechnology company that develops intracellular therapeutics designed to deliver biologics and drugs directly into target cells for the treatment of devastating and complex medical conditions. The organization primarily focuses on addressing severe neuromuscular disorders, with a specific emphasis on advancing clinical treatments for patients suffering from Duchenne muscular dystrophy. To support its research and development pipeline, the enterprise secured $59 million in Series A funding, marking the largest initial venture capital round for a startup originating from Ohio State University. The corporate leadership team includes Chief Executive Officer Dipal Doshi, President of Research and Development Natarajan Sethuraman, and Chief Operating Officer Nathan J. Dowden, while the board of directors features Kush M. Parmar from the venture capital firm 5AM Ventures. Entrada Therapeutics was founded in 2018 by Ohio State University professor Dehua Pei.
Entrada Therapeutics has raised $175.0M across 2 funding rounds.
Entrada Therapeutics has raised $175.0M in total across 2 funding rounds.
Entrada Therapeutics has raised $175.0M across 2 funding rounds. Most recently, it raised $116.0M Series B in March 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 31, 2021 | $116M Series B | Wellington Management | Kush Parmar, Agent Capital, Cureduchenne Ventures, Goldman Sachs, Greenspring Associates, MPM Capital, MRL Ventures Fund, Point72, Qatar Investment Authority, Redmile Group, Roche, TCGX, Undisclosed Global Investment Firm | Announced |
| Dec 18, 2018 | $59M Series A | Kush Parmar, Todd Foley | Agent Capital, Christine Brennan, Anja Harmeier | Announced |
Entrada Therapeutics has raised $175.0M in total across 2 funding rounds.
Entrada Therapeutics's investors include Wellington Management, Kush Parmar, Agent Capital, CureDuchenne Ventures, Goldman Sachs, Greenspring Associates, MPM Capital, MRL Ventures Fund, Point72, Qatar Investment Authority, Redmile Group, Roche.